• 3-(5-dipropylaminomethyloxazol-2-yl)-8-fluoro-5-methyl-5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepin-6-one
PubChem CID
Chemical and physical data
Molar mass411.472 g·mol−1
3D model (JSmol)
  • CCCN(CC1=CN=C(C2=C(CN(C(C3=C4C=CC(F)=C3)=O)C)N4C=N2)O1)CCC
  • InChI=1S/C22H26FN5O2/c1-4-8-27(9-5-2)12-16-11-24-21(30-16)20-19-13-26(3)22(29)17-10-15(23)6-7-18(17)28(19)14-25-20/h6-7,10-11,14H,4-5,8-9,12-13H2,1-3H3

Ro48-8684 is a water-soluble benzodiazepine derivative developed by Hoffman-LaRoche in the 1990s, which was designed along with Ro48-6791 as an improved replacement for midazolam, but ultimately proved to have little advantages over the parent drug and has not been introduced into clinical practice.[1][2]

See also


  1. ^ van Gerven JM, Roncari G, Schoemaker RC, Massarella J, Keesmaat P, Kooyman H, et al. (November 1997). "Integrated pharmacokinetics and pharmacodynamics of Ro 48-8684, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects". British Journal of Clinical Pharmacology. 44 (5): 487–93. doi:10.1046/j.1365-2125.1997.t01-1-00613.x. PMC 2042863. PMID 9384466.
  2. ^ Albrecht S, Hering W, Ihmsen H, Schwilden H, Schüttler J (October 1999). "[Pharmacokinetic-pharmacodynamic modeling in phase II of drug development. A comparative study with young and old volunteers with benzdiazepine as an example]". Anästhesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie. 34 (10): 634–7. doi:10.1055/s-1999-213. PMID 10548960.